RAP - The Main Game, page-1100

RAP ASX release March 15 2017

"The company advises it remains on track to complete enrollment, release top line results and submit its de novo submission to the FDA in the 1st half of C2017"

It is a thought out and composed RAP statement attempting to be very clear of the order of things to come.

There is always room to be optimistic. RAP may be enrolling 100 - 130 a week in the peak of Boston USA winter (6C today) and complete enrollment within next 2 weeks.

Now I guess that all the diagnostic data from Dr's examination, xray diagnostic, and Dr's Diagnosis will be entered into a data base for each enrollment as the trial proceeds as will the Resapp dx diagnosis held in another data base.

I see the rapid comparing of computer entered data sets will take maybe a couple weeks to sift and sort and then top line results officially released, then we submit our de novo submission to the FDA in the 1st half of C2017.

The clearest pathway for CEmark application and one favored by our trial agents is to apply for CEmark in parallel with FDA submission.

CEmark will most likely happen way before FDA approval.

I see a 10 + badger rise over a few months from release of top line results from FDA
SMARTCOUGH -C trial.

With top line results, there is every possibility that revenue will start to flow from all countries with telehealth we sign covered under the CEmark in 1st financial quarter of 2017 - 2018

game on

LUV RAP
MB




p